[Abnormal movements caused by L-DOPA in patients with Parkinson's disease: correlation with the plasma concentrations of DOPA and O-methyl-DOPA].
This study involved twleve parkinsonian patients exposed to abnormal movements provoked by L-DOPA. Including six patients with "mid-dose" dyskinesias and six others with "onset and end of dose" dyskinesias, Correlation between the circumstances of onset of abnormal movements and plasma concentrations of DOPA and O-methyl-DOPA, after administration of a dose of L-DOPA + IDC, gave the following results: 1) mid-dose dyskinesias appeared with the highest plasma concentrations of DOPA, at the maximum therapeutic effect; 2) onset and end of dose occurred during rise and fall in plasma levels of DOPA, coinciding with the relief and the reappearance of parkinsonian symptoms respectively; 3) no correlation could be established between plasma concentrations of O-methyl-DOPA and the duration of the period of clinical remission or of abnormal movements. These biochemical data, completed by the neuropharmacological study of one patient with onset and end of dose abnormal movements suggest the predominant role of a disturbance in central dopaminergic mechanisms in the genesis of abnormal movements, whatever their nature.
D004295:Dihydroxyphenylalanine / Q000097:blood*; D004305:Dose-Response Relationship, Drug; D004409:Dyskinesia, Drug-Induced / Q000097:blood*; D006801:Humans; D007980:Levodopa / Q000009:adverse effects*; D008750:Methyldopa / Q000097:blood*; D008875:Middle Aged; D010300:Parkinson Disease / Q000188:drug therapy*
D007980:Levodopa; D008750:Methyldopa; D004295:Dihydroxyphenylalanine
Mouvements anormaux provoqués par la L-DOPA dans la maladie de Parkinson: corrélation avec les concentrations plasmatiques de DOPA et de O-méthyl-DOPA.